Abstract:Background: Kaempferol is a flavonoid derived from the herb, Kaempferia galanga L., in addition to exhibiting a wide range of pharmacological properties, kaempferol is also an anti-inflammatory, anti-lipid metabolizing, and anti-oxidative stress agent. The underlying molecular mechanisms of its effects on vascular endothelial growth factor (VEGF) secretion and activation of hepatic stellate cells (HSCs) are yet unknown. Activated HSCs induces VEGF release and extracellular matrix (ECM) accumulation which are important factors in hepatic fibrosis. Purpose: Our aim is to explore how kaempferol may affect hepatic fibrosis and the mechanisms behind its effects. Methods: The in vivo model was Sprague-Dawley rats induced with carbon tetrachloride (CCl4). Histological staining was used to observe histological features of the liver. The levels of (alanine aminotransferase) ALT and (aspartate aminotransferase) AST were detected by the corresponding kits. Platelet-derived growth factor (PDGF) was used to stimulate the HSC-T6 rat hepatic stellate cells. The mechanisms underlying this process were investigated using a variety of molecular approaches, including immunofluorescence, RT-qPCR, and western blotting. Moreover, intracellular Ca2+ were observed by laser confocal microscope. Results: It was found that kaempferol significantly reduced the expression of ASIC1a, VEGF, alpha-SMA and CollagenI proteins in a model of CCl4-induced hepatic fibrosis in rats. In HSC-T6, kaempferol inhibits activation of HSCs by decreasing expression of ASIC1a, eIF2 alpha, p-eIF2 alpha and ATF-4. Laser confocal fluorescence showed that kaempferol inhibited Ca2+ influx and reduced Ca2+ concentration around the endoplasmic reticulum. Molecular docking and cellular thermal shift assay (CETSA) results further indicated that kaempferol interacted with ASIC1a. We found that kaempferol may promote the degradation of ASIC1a and inhibited ASIC1a- mediated upregulation of ERS. Conclusion: The data from our in vivo experiments demonstrate that kaempferol effectively attenuates hepatic fibrosis. In vitro studies we further propose a novel mechanism of kaempferol against hepatic fibrosis which can interact with ASIC1a and promote ASIC1a degradation while inhibiting the activation and VEGF release of HSCs by suppressing the ASIC1a-eIF2 alpha-ATF-4 signaling pathway.

Kaempferol Inhibits Multiple Pathways Involved in the Secretion of Inflammatory Mediators from LPS‑induced Rat Intestinal Microvascular Endothelial Cells.

Protective Effect of Kaempferol on LPS-Induced Inflammation and Barrier Dysfunction in a Coculture Model of Intestinal Epithelial Cells and Intestinal Microvascular Endothelial Cells.

Kaempferol Prevents Angiogenesis of Rat Intestinal Microvascular Endothelial Cells Induced by LPS and TNF-α Via Inhibiting VEGF/Akt/p38 Signaling Pathways and Maintaining Gut-Vascular Barrier Integrity.

Kaempferol Relieves the DSS-induced Chronic Colitis in C57BL/6J Mice, Alleviates Intestinal Angiogenesis, and Regulates Colonic Microflora Structure

Kaempferol-3-O-glucorhamnoside Inhibits Inflammatory Responses Via MAPK and NF-κB Pathways in Vitro and in Vivo.

Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis

Quercetin Attenuates Adhesion Molecule Expression in Intestinal Microvascular Endothelial Cells by Modulating Multiple Pathways

Kaempferol Reduces Obesity, Prevents Intestinal Inflammation, and Modulates Gut Microbiota in High-Fat Diet Mice.

Protective Effect of Kaempferol on LPS Plus ATP-Induced Inflammatory Response in Cardiac Fibroblasts

Kaempferol suppression of acute colitis is regulated by the efflux transporters BCRP and MRP2

Kaempferol enhances the suppressive function of Treg cells by inhibiting FOXP3 phosphorylation.

Kaempferol alleviates LPS-ATP mediated inflammatory injury in splenic lymphocytes via regulation of the pyroptosis pathway in mice.

Kaempferol attenuates inflammation in lipopolysaccharide‐induced gallbladder epithelial cells by inhibiting the MAPK/NF‐κB signaling pathway

Kaempferol Remodels Liver Monocyte Populations and Treats Hepatic Fibrosis in Mice by Modulating Intestinal Flora and Metabolic Reprogramming

Kaempferol regulates MAPKs and NF-κB signaling pathways to attenuate LPS-induced acute lung injury in mice

Kaempferol alleviates adipose tissue inflammation and insulin resistance in db/db mice by inhibiting the STING/NLRP3 signaling pathway

Apigenin And Kaempferol Inhibit Lps-Induced Inflammatory Responses By Regulating Intracellular Translocation Of Rna-Binding Protein Hur In Macrophages

Rebalancing of the gut flora and microbial metabolism is responsible for the anti-arthritis effect of kaempferol

Pharmacological Effects of Polyphenol Phytochemicals on the Intestinal Inflammation via Targeting TLR4/NF-kappa B Signaling Pathway

Kaempferol attenuates carbon tetrachloride (CCl4)-induced hepatic fibrosis by promoting ASIC1a degradation and suppression of the ASIC1a-mediated ERS

Flavonoids Derived From Exocarpium Citri Grandis Inhibit Lps-Induced Inflammatory Response Via Suppressing Mapk And Nf-Kappa B Signalling Pathways